Dr. Shrikant Karwa, the founder of the Group, has, to his credit, a doctoral thesis on Principles of Liquid-phase Catalytic Hydrogenation and a few international publications and review articles in the same field. With no industrial experience and only his university research as his asset, he directly ventured to transform his technological insight into industrial reality.
Presently, the group comprises of 110 people with annual turn over of $ 9 millions. The core activity is manufacture of pharmaceutical intermediates and fine chemicals. This is backed up by well equipped research lab and pilot plant for development of new products and up-gradation of existing processes.
0 Comments